Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Delcath Systems, a medical technology company specializing in cancer treatment, has announced that the Robert Franz Cancer Research Center, a part of the Providence Cancer Center, located in Portland, Oregon, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the company's percutaneous hepatic perfusion system.
Subscribe to our email newsletter
This pivotal multi-center study for the isolated, high dose delivery of the anticancer agent melphalan is led by the National Cancer Institute. Providence, the 10th center to join this trial, will be able to provide this treatment option to a previously unreached patient population in the Pacific Northwest region of the US.
Delcath is announcing the expansion of this trial following Providence entering into a clinical research agreement with Delcath. Walter Urba, medical director of the Robert Franz Cancer Research Center and Earle Chiles Research Institute – a part of the Providence Cancer Center – will serve as the principal investigator of the study.
Richard Taney, president and CEO of Delcath, said: “The addition of Providence Cancer Center to this trial further propels Delcath towards its goal of completing enrollment in 2009. For decades, Dr Urba has been a leader in the research and implementation of melanoma treatments and he brings to this trial significant clinical and academic experience.”